High STAT4 expression correlates with poor prognosis in acute myeloid leukemia and facilitates disease progression by upregulating VEGFA expression-Reference-Cited by-同舟云学术

High STAT4 expression correlates with poor prognosis in acute myeloid leukemia and facilitates disease progression by upregulating VEGFA expression

Published:2024-01-01 Issue:1 Volume:19 Page:
ISSN:2391-5463
Container-title:Open Medicine
language:en
Short-container-title:

Author:

Li Aohang¹,Wu Jingxuan²

Affiliation:

1. Clinical Laboratory Center, Beijing Friendship Hospital, Capital Medical University , Beijing , China

2. Research Ward, Beijing Friendship Hospital, Capital Medical University , Xicheng District , Beijing , China

Abstract

Abstract The aim of our study is to explore the mechanism of transcription-4 (STAT4) in acute myeloid leukemia (AML). STAT4 level in AML bone marrow samples/cells was analyzed using bioinformatics and quantitative real-time PCR. The correlation between high STAT4 expression and the prognosis of AML patients was analyzed. The viability, apoptosis, and angiogenesis of AML cells were detected. The levels of STAT4, vascular endothelial growth factor A (VEGFA), and apoptosis-related proteins (Bcl-2 and Bax) in transfected AML cells were examined. STAT4 level was upregulated in AML. STAT4 silencing decreased the viability and angiogenesis, yet increased the apoptosis of AML cells, while overexpressed STAT4 did conversely. VEGFA silencing counteracted the impacts of overexpressed STAT4 upon promoting viability and angiogenesis as well as repressing the apoptosis of AML cells. High STAT4 expression was correlated with poor prognosis of AML patients and facilitated disease progression via upregulating VEGFA expression.

Publisher

Walter de Gruyter GmbH

Link

https://www.degruyter.com/document/doi/10.1515/med-2023-0840/pdf

Reference44 articles.

1. Stief SM, Hanneforth AL, Weser S, Mattes R, Carlet M, Liu WH, et al. Loss of KDM6A confers drug resistance in acute myeloid leukemia. Leukemia. 2020;34(1):50–62.

2. Sweta J, Khandelwal R, Srinitha S, Pancholi R, Adhikary R, Ali MA, et al. Identification of high-affinity small molecule targeting IDH2 for the clinical treatment of acute myeloid leukemia. Asian Pac J Cancer Prev. 2019;20(8):2287–97.

3. Khan N, Patel D, Trivedi C, Kavani H, Pernes T, Medvedeva E, et al. Incidence of acute myeloid leukemia and myelodysplastic syndrome in patients with inflammatory bowel disease and the impact of thiopurines on their risk. Am J Gastroenterol. 2020;116(4):741–7.

4. Linet MS, Gilbert ES, Vermeulen R, Dores GM, Yin SN, Portengen L, et al. Benzene exposure response and risk of myeloid neoplasms in chinese workers: a multicenter case-cohort study. J Natl Cancer Inst. 2019;111(5):465–74.

5. Gillies M, Haylock R, Hunter N, Zhang W. Risk of leukemia associated with protracted low-dose radiation exposure: updated results from the national registry for radiation workers study. Radiat Res. 2019;192(5):527–37.